Furthermore, clinical trials, structural modifications, and biomimetic synthesis may lead to the discovery of promising inhibitors of HMGR and XO, which could contribute to the treatment of hyperuricemia and lowering cholesterol. This evidence concerns the gene XDH and hyperuricemia.